isrg-20230515

0001035267-23-000142.txt : 20230516 0001035267-23-000142.hdr.sgml : 20230516 20230516080337 ACCESSION NUMBER: 0001035267-23-000142 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230515 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTUITIVE SURGICAL INC CENTRAL INDEX KEY: 0001035267 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 770416458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30713 FILM NUMBER: 23925624 BUSINESS ADDRESS: STREET 1: 1020 KIFER ROAD CITY: SUNNYVALE STATE: CA ZIP: 94086 BUSINESS PHONE: 4085232100 MAIL ADDRESS: STREET 1: 1020 KIFER ROAD CITY: SUNNYVALE STATE: CA ZIP: 94086 8-K 1 isrg-20230515.htm 8-K isrg-20230515

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2023

INTUITIVE SURGICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-30713

77-0416458

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

1020 Kifer Road

Sunnyvale, California 94086

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (408) 523-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ISRG

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 5.02.						Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 15, 2023, the Board of Directors of Intuitive Surgical, Inc. (the “Company” or “Intuitive”) promoted David J. Rosa to the role of President of the Company, effective May 16, 2023. In connection with Mr. Rosa’s promotion, Gary S. Guthart, Ph.D., will cease to hold the title of President and will continue to serve as the Company’s Chief Executive Officer and as a member of its Board of Directors. Mr. Rosa will continue to report directly to Dr. Guthart.

David J. Rosa, age 55, joined Intuitive in March 1996 and has held leadership positions across the organization in commercial, engineering, clinical development, marketing, and product development. In April 2011, Mr. Rosa was promoted to the position of Senior Vice President, Emerging Procedures & Technology, and transitioned to the position of Senior Vice President, Scientific Affairs. In August 2014, Mr. Rosa was promoted to the position of Executive Vice President and Chief Scientific Officer. In June 2015, Mr. Rosa was appointed as Executive Vice President and Chief Commercial Officer. In January 2019, Mr. Rosa took on additional responsibility as Executive Vice President and Chief Business Officer. In January 2022, Mr. Rosa transitioned to Chief Strategy and Growth Officer. Mr. Rosa also currently serves on the Board of Directors of Kardium Inc. Mr. Rosa graduated magna cum laude with a B.S. in Mechanical Engineering from California Polytechnic University at San Luis Obispo. He also holds a Master of Science in Mechanical Engineering from Stanford University.

In connection with Mr. Rosa’s promotion to President, his annual base salary was increased from $652,468 to $700,000, and his targeted bonus opportunity under the Company’s Corporate Incentive Program for the fiscal year 2023 performance period was increased from 100% to 120% of his base salary. In addition, Mr. Rosa will receive, pursuant to the Company’s Amended and Restated 2010 Incentive Award Plan, grants of (i) an option to purchase shares of the Company’s common stock with a value of $1,500,000 (“Target Stock Option Value”), (ii) restricted stock units (“RSUs”) with a value of $1,500,000 (“Target RSU Value”) and (iii) performance stock units (“PSUs”) with a value of $2,000,000 (“Target PSU Value”), whose metrics are consistent with the 2023 annual grant of PSUs. The number of shares underlying the stock option will be determined by dividing the Target Stock Option Value by one-third of the 60 trading-day average closing price of the Company’s common stock, as reported by Nasdaq, through the last trading day of the month prior to the grant date (the “60 Trading-Day Average”). The number of RSUs and target number of PSUs will be determined by dividing each of the Target RSU Value and Target PSU Value by the 60 Trading-Day Average. The shares subject to the option will vest 25% on the first anniversary of the grant and 1/48 per month thereafter, and the shares subject to the RSUs will vest 25% annually over a four-year period. The shares subject to the PSUs will vest as to 0-125% of the target number of PSUs after a three-year period based on the achievement of certain performance objectives.

There are no transactions in which Mr. Rosa had or will have a direct or indirect material interest that are required to be reported under Item 404(a) of Regulation S-K.


Item 7.01.						Regulation FD Disclosure.

On May 16, 2023, the Company issued a press release announcing executive leadership changes, which press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.


Item 9.01.						Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description.
99.1						Press release issued by Intuitive Surgical, Inc., dated May 16, 2023.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTUITIVE SURGICAL, INC.

Date: May 16, 2023

By:

/S/ JAMIE E. SAMATH

Name: Jamie E. Samath

Title: Senior Vice President and Chief Financial Officer

EX-99.1 2 q223ex-991executiveleaders.htm EX-99.1 Document

Exhibit 99.1



						Contact: Global Public Affairs +1-202-997-7373

INTUITIVE ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

Dave Rosa named President; Gary Guthart remains Chief Executive Officer

SUNNYVALE, CALIF. May 16, 2023 – Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced executive leadership changes as the Company continues expanding globally and advancing minimally invasive care.

Dave Rosa has been promoted to the role of President, leading Intuitive’s product, digital, quality, regulatory, supply chain, manufacturing, and commercial teams. He will oversee the Company’s core business, driving product, digital, and commercial excellence and delivery of Intuitive’s annual and mid-term strategies and goals. Rosa is a 27-year Company veteran who has held key leadership positions across the business, including in the commercial, engineering, clinical development, marketing, and product development organizations. Most recently, Rosa served as Executive Vice President and Chief Strategy and Growth Officer.

“As Intuitive has grown and demand for robotic-assisted surgery has increased, we remain focused on our mission to advance minimally invasive care and our commitment to working with customers to meaningfully improve patient outcomes,” said Intuitive Chief Executive Officer Gary Guthart. “Aligning our core business functions under Dave, a proven and outstanding leader with broad and deep experience across Intuitive, equips us to meet future opportunities to collaborate with hospitals and healthcare systems to address healthcare challenges at significant scale.”

“Our efforts over the past 27 years have created great opportunities to serve our customers better and in new ways. I look forward to leading our continued development of innovative, outcomes-focused products, services, and solutions,” said Rosa. “Intuitive aims to deliver excellence in customer experience, industry-leading innovation, and meaningful expansion of minimally invasive care. My goal is to help the Company continue to deliver on these aims.”

Guthart will continue as Intuitive’s CEO, leading the Company and focusing on Intuitive’s presence in the market, its overall strategy, governance, and culture, as well as nurturing early-stage business and product initiatives. Guthart has been with Intuitive for 27 years and has served as CEO since 2010.

In addition, Bob DeSantis will assume the newly created role of Executive Vice President and Chief Strategy and Corporate Operations Officer, leading strategic planning, operational structure, and management for the business. Previously, DeSantis served as Executive Vice President and Chief Product Officer. In his decade with Intuitive, he has been pivotal in advancing the development and manufacturing of the Company’s industry-leading robotic platforms.

Rosa and DeSantis will continue to report to Guthart, and all executive leadership changes are effective immediately.

Intuitive pioneered the field of robotic-assisted, minimally invasive surgery more than two decades ago with the da Vinci surgical system. Since then, more than 12 million procedures have been performed using da Vinci systems, with more than 66,000 surgeons worldwide trained on da Vinci systems.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Product and brand names/logos are trademarks or registered trademarks of Intuitive Surgical or their respective owner. See www.intuitive.com/trademarks.

For more information, please visit the Company’s website at www.intuitive.com.

Page 1 of 2

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding executive leadership changes, the Company’s ability to address healthcare challenges at significant scale, the Company’s continued development of innovative, outcomes-focused products, services and solutions and the Company’s aim to deliver excellence in customer experience, industry-leading innovation and meaningful expansion of minimally invasive care across product and digital solutions, clinical applications and geographies. These statements reflect the judgment of the Company's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which impacts customer spending and the Company’s costs, including increased inflation and interest rates, the conflict in Ukraine, disruption to the Company’s supply chain; curtailed or delayed capital spending by hospitals; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals, clearances, or certifications from regulatory authorities, or notified bodies; the impact of global and regional economic and credit market conditions on healthcare spending; the risk of the Company’s inability to comply with complex regulations; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company’s completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which the Company operates; risks associated with the Company’s operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company’s reliance on sole-sourced and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Company’s Quarterly report on Form 10-Q for the quarter ended March 31, 2023 as updated by the Company’s other filings with the Securities and Exchange Commission. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted,” and similar words and expressions are intended to identify forward-looking statements.

Page 2 of 2

EX-101.SCH 3 isrg-20230515.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 isrg-20230515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 isrg-20230515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information Document	May 02, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	May 15, 2023
Entity Registrant Name	INTUITIVE SURGICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	000-30713
Entity Tax Identification Number	77-0416458
Entity Address, Address Line One	1020 Kifer Road
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94086
City Area Code	408
Local Phone Number	523-2100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ISRG
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001035267
Amendment Flag	false

XML 7 isrg-20230515_htm.xml IDEA: XBRL DOCUMENT 0001035267 2023-05-02 2023-05-02 0001035267 false 8-K 2023-05-15 INTUITIVE SURGICAL, INC. DE 000-30713 77-0416458 1020 Kifer Road Sunnyvale CA 94086 408 523-2100 false false false false Common Stock, par value $0.001 per share ISRG NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ') L%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !R0+!6H"NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*(EI#R;-I:.G#@8K;.QF;+4UBV-C:R1]^SE>FS*V!]C1TN]/ MGT"M\D*Y@,_!>0QD,#Y,MA^B4'[#SD1> $1U1BMCF1)#:AY=L)+2,YS 2_4A M3PA-5:W!(DDM2<(,+/Q"9%VKE5 !);EPQ6NUX/UGZ#-,*\ >+0X4H2YK8-T\ MT5^FOH4[8(81!AN_"Z@78J[^BQ''G.I1UJ>'O:O^1U"S-$ MDH/"]"L:01>/&W:;_,JWCX<=ZYJJX46U*NKUH6Y$Q05?O<^N/_SNPM9I621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ') L%:0-.!45P0 )X0 8 >&PO=V]R:W-H965T&UL ME9AM;^HV%,>_BI5-TR;1XH3'=A2)TH=%?;@,Z+W2IKTPB0&KB9TY3BG??L9PD+ 5GW'SEDPTC)J%2BAB+E.A)-%\>>.,W.M;KVT# M\B>^"KY)C\Z)?96%4N]VX(7F;!4CY6T3<1FO6-TW=(R)Z__136 L0+T"U,OE6B?DQNJ#:_+W:)$:#:7\IPIH MI]"N5K#]?9TF+. W#C1PRO4'=X:__.1VZ>$7ZO@:V'J92+GVX17P>'A_8LG M!*)=0+3/@YAP+90M:$B@+2IY<"5;/;?3('7EZQ1D'51OWUI3OA*V@(#XRN)* M+ES'?YV_^7/_ZSV9O4T?_?'HN4'\U_$E@M@M$+OG(/HR4#I1.N__!ID9R!]1 MFHQ5)HW>PC&LY,;%[^X1PEY!V#N'\$%$G+QF\8+K*A!<@U)ZT:(]%RMJO^#I MG\,S9Y_$#Z'MQ%($.]LX38-P0I[A M.?)%5E815W2I1\F36((3314+$4:7E@9,?XAR;$?0;W.UD96NB\O-,BFW'RSB M&-S1ZN#^$%PQ&R9:?0@95.:P1G,\PM#*]3M9*88]2(=+S6A>=2 MBA&5ZX"+&_@W+8SA$A(3QYG<^T5:284++5F4HDU>^KZ+>_-,12(01L@5>8'V MUH)%E3RX2BU/Z?(N;M$3S2\"2 ^'^;7[I. R!,OYLER>J!^N5TM6^KV+V_-W M9'Z:9D!6"XC+U@*6CN_B!CT7!M9&M22N]^OB-S+C00;]MJUDPI5L?$"-C,J M>&^0A&D"IIIQ\C.]I-0E";QNNF8:P_;*-<##37NN66C;;[:-%ZJR^6H$_-GT M$2,I#=_#S?F0,7+_&:R97/&3WVDU0J^CV=WH3XSIZ,O_+*>_C[E>V2P]@H)9 M6P=)F*RL;8U@7;]YI=%[N$_OT<8P%S08K0_3X),\\6HH7 H^S%S:ZGC='D96 M.K^'F_8(YF>8S]&'B*TJ>7"!DTEJ'NTV[<[]A=FRI"3B2Q"BESWP;;W;#.\& M1B7Y!G2A#&QG\],U9V 8]@&XOU3*' 9V3UO\2V+X'U!+ P04 " !R0+!6 MGZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG> MW&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4 MD*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF M8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,) M;2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z: M\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9 ML^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E M\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ- MLPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O M-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*= M##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ M P04 " !R0+!6EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P M#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606 MIW.D5XA-/E M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU M@LD/['X 4$L#!!0 ( ') L%8<.&7J/P$ #P" / >&PO=V]R:V)O M;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=1 M5*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU M!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[ MMP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8? M1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.( M<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W M\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q= MZ*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ 9(9 0 SP, !, !; M0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\: MJ_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)X MKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\ MC<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&) M7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\ MP68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B M6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " !R0+!6 M!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM M;%!+ 0(4 Q0 ( ') L%:@*YSE[@ "L" 1 " :\ M !D;V-0&UL4$L! A0# M% @ 7!E&UL4$L%!@ ) D /@( /H3 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports isrg-20230515.htm isrg-20230515.xsd isrg-20230515_lab.xml isrg-20230515_pre.xml q223ex-991executiveleaders.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "isrg-20230515.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "isrg-20230515.htm" ] }, "labelLink": { "local": [ "isrg-20230515_lab.xml" ] }, "presentationLink": { "local": [ "isrg-20230515_pre.xml" ] }, "schema": { "local": [ "isrg-20230515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "isrg", "nsuri": "http://www.intuitivesurgical.com/20230515", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "isrg-20230515.htm", "contextRef": "i20cdcbacf3c34e79a8d3a64244ff294b_D20230502-20230502", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information Document", "menuCat": "Cover", "order": "1", "role": "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "isrg-20230515.htm", "contextRef": "i20cdcbacf3c34e79a8d3a64244ff294b_D20230502-20230502", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.intuitivesurgical.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001035267-23-000142-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001035267-23-000142-xbrl.zip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